Broadcast Date: April 22, 2021
Time: 2:00 pm PT, 5:00 pm ET

Molecular residual disease (MRD) detection is emerging as a powerful and non-invasive tool for improving the management of cancer in the post-operative treatment setting. Using circulating tumor DNA can help accurately identify MRD sooner than current standard of care tools but choosing the right assay with proven performance and high sensitivity is key.

Join us for this live Clinical OMICs webinar for a dynamic discussion with our esteemed guests Dr. Gregory Botta from UC San Diego and Dr. Angel Rodriguez from Natera, who will review the value of a tumor informed approach to optimize patient management in the adjuvant treatment setting.

A live Q&A session will follow the presentations, offering a chance to pose questions to our expert panelists.

Produced with support from:

Natera logo
Gregory Botta, MD, PhD

Gregory Botta, MD, PhD
Medical Oncologist, UC San Diego

Angel Rodriguez, MD

Angel Rodriguez, MD
Medical Director, Oncology, Natera